Standard Pre- and Postoperative Determination of Chromogranin A in Resectable Non-Functioning Pancreatic Neuroendocrine Tumors—Diagnostic Accuracy: NF-pNET and Low Tumor Burden
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background: Chromogranin A (CgA) is often used in metastatic patients with nonfunctioning pancreatic neuroendocrine tumors (NF-pNET). The aim of this study is to assess the diagnostic accuracy of CgA in patients with low tumor burden. Methods: Resectable patients with NF-pNET without metastases at time of diagnosis were included between 2002 and 2013 in the Academic Medical Center of Amsterdam. CgA was determined at time of diagnosis and during follow-up according to a standardized method. The upper reference range was 94 µg/l. Results: Overall, 47 patients were included in this study. CgA was elevated preoperatively in only 10 patients (27%). In the detection of metastases during follow-up, the positive predictive value for CgA was 50% and negative predictive value was 81%. In 50% of the patients with an elevated CgA during follow-up, this test result was false-positive. Conclusions: The diagnostic accuracy of CgA was low preoperatively in patients with resectable NF-pNET and low tumor burden. In the detection of recurrent disease after curative resection of NF-pNET, the diagnostic accuracy of CgA was moderate (50%). We conclude that the routine measurement of CgA at time of diagnosis or during follow-up after curative resection had limited value in patients with resectable NF-pNET.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All patients with metastatic disease had elevated CgA concentrations whereas half of patients with localized disease had elevated CgA, strengthening the idea that CgA is more sensitive in disseminated disease compared to localized disease [16,17,18,30,31].”
From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [17]
Citations
Cites
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Levey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
Rindi, G., Klöppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., Erikssson, B., Falchetti, A., Falconi, M., Komminoth, P., et al. (2006) · Virchows Archiv · doi:10.1007/s00428-006-0250-1 · Cited by 1,547
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
NANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., et al. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb168 · Cited by 574
Falconi, M., Bartsch, D. K., Eriksson, B., Klöppel, G., Lopes, J. M., O'Connor, J. M., Salazar, R., Taal, B. G., Vullierme, M. P., & O'Toole, D. (2012) · Neuroendocrinology · doi:10.1159/000335587 · Cited by 526
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor
Bettini, R., Partelli, S., Boninsegna, L., Capelli, P., Crippa, S., Pederzoli, P., Scarpa, A., & Falconi, M. (2011) · Surgery · doi:10.1016/j.surg.2011.02.022 · Cited by 358
Nobels, F. R. E., Kwekkeboom, D. J., Coopmans, W., Schoenmakers, C. H. H., Lindemans, J., De Herder, W. W., Krenning, E. P., Bouillon, R., & Lamberts, S. W. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4145 · Cited by 352
Yang, Z., Tang, L. H., & Klimstra, D. S. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31821a0696 · Cited by 332
Stridsberg, M., Öberg, K., Li, Q., Engström, U., & Lundqvist, G. (1995) · Journal of Endocrinology · doi:10.1677/joe.0.1440049 · Cited by 278
Lee, L. C., Grant, C. S., Salomao, D. R., Fletcher, J. G., Takahashi, N., Fidler, J. L., Levy, M. J., & Huebner, M. (2012) · Surgery · doi:10.1016/j.surg.2012.08.038 · Cited by 269
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
Baudin, E., Gigliotti, A., Ducreux, M., Ropers, J., Comoy, E., Sabourin, J., Bidart, J., Cailleux, A., Bonacci, R., Ruffié, P., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.635 · Cited by 250
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
A comparison between three commercial kits for chromogranin A measurements
Stridsberg, M., Eriksson, B., Oberg, K., & Janson, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770337 · Cited by 202
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177 · cited 1×
“The studies did describe the positive correlation between tumor load and the degree of elevated CgA (9,22,50).”
BackgroundChromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
Zatelli, M. C., Torta, M., Leon, A., Ambrosio, M. R., Gion, M., Tomassetti, P., De Braud, F., Delle Fave, G., Dogliotti, L., Uberti, E. C. D., et al. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0001 · Cited by 159
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours
Seregni, E. C., Ferrari, L., Bajetta, E., Martinetti, A., & Bombardieri, E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s69 · Cited by 150
Chromogranin A in uremia: Progressive retention of immunoreactive fragments
Hsiao, R. J., Mezger, M., & O’Connor, D. T. (1990) · Kidney International · doi:10.1038/ki.1990.71 · Cited by 146
Plasma chromogranin a in patients with inflammatory bowel disease
Sciola, V., Massironi, S., Conte, D., Caprioli, F., Ferrero, S., Ciafardini, C., Peracchi, M., Bardella, M. T., & Piodi, L. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20851 · Cited by 123
Diagnostic value of plasma chromogranin A in neuroendocrine tumours
Tomassetti, P., Migliori, M., Simoni, P., Casadei, R., De Iasio, R., Corinaldesi, R., & Gullo, L. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200101000-00010 · Cited by 119
Sanduleanu, S., De Bruïne, A., Stridsberg, M., Jonkers, D., Biemond, I., Hameeteman, W., Lundqvist, G., & Stockbrügger, R. W. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00890.x · Cited by 114
Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours
Oberg, K. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-10-0280 · Cited by 104
de Laat, J. M., Pieterman, C. R. C., Weijmans, M., Hermus, A. R., Dekkers, O. M., de Herder, W. W., van der Horst‐Schrivers, A. N. A., Drent, M. L., Bisschop, P. H. L. T., Havekes, B., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1800 · Cited by 88
Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E. (2008) · Pancreatology · doi:10.1159/000152000 · Cited by 84
Biological and Molecular Aspects of Gastroenteropancreatic Neuroendocrine Tumors
Rindi, G., Villanacci, V., & Ubiali, A. (2000) · Digestion · doi:10.1159/000051851 · Cited by 81
Chromogranins — New Sensitive Markers for Neuroendocrine Tumors
Eriksson, B., Arnberg, H., Ouberg, K., Hellman, U., Lundqvist, G., Wernstedt, C., & Wilander, E. (1989) · Acta Oncologica · doi:10.3109/02841868909111201 · Cited by 76
Cimitan, M., Buonadonna, A., Cannizzaro, R., Canzonieri, V., Borsatti, E., Ruffo, R., & Appollonia, L. D. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg279 · Cited by 76
Limitations of Chromogranin A in clinical practice
Marotta, V., Nuzzo, V., Ferrara, T., Zuccoli, A., Masone, M., Nocerino, L., Del Prete, M., Marciello, F., Ramundo, V., Lombardi, G., et al. (2012) · Biomarkers · doi:10.3109/1354750x.2012.654511 · Cited by 61
Böttcher, J., Hansch, A., Pfeil, A., Schmidt, P. M., Malich, A., Schneeweiss, A., Maurer, M. H., Streitparth, F., Teichgräber, U. K.-M., & Renz, D. M. (2013) · European Journal of Radiology · doi:10.1016/j.ejrad.2013.06.013 · Cited by 53
Abou‐Saif, A., Gibril, F., Ojeaburu, J. V., Bashir, S., Entsuah, L. K., Asgharian, B., & Jensen, R. T. (2003) · Cancer · doi:10.1002/cncr.11473 · Cited by 46
Chou, W., Hung, Y., Hsu, J., Chen, J., Lu, C., Hwang, T., Rau, K., Yeh, K., Chen, T., & Sun, C. (2012) · Neuroendocrinology · doi:10.1159/000333853 · Cited by 46
Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
Paik, W. H., Ryu, J. K., Song, B. J., Kim, J., Park, J. K., Kim, Y.-T., & Yoon, Y. B. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.5.750 · Cited by 44
Nölting, S., Kuttner, A. J., Lauseker, M., Vogeser, M., Haug, A. R., Herrmann, K. A., Hoffmann, J. N., Spitzweg, C., Göke, B., & Auernhammer, C. J. (2012) · Cancers · doi:10.3390/cancers4010141 · Cited by 41
The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome.
Sidhu, R., McAlindon, M. E., Leeds, J. S., Skilling, J., & Sanders, D. S. (2009) · PubMed · Cited by 38
Biochemical diagnosis of neuroendocrine GEP tumor.
Öberg, K. (1997) · PubMed Central · Cited by 38
Lukinius, A., Stridsberg, M., & Wilander, E. (2003) · Pancreas · doi:10.1097/00006676-200307000-00006 · Cited by 34
Metser, U., Jones, C., Jacks, L. M., Bernardini, M. Q., & Ferguson, S. E. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31822925c0 · Cited by 34
Ferrari, L., Seregni, E., Lucignani, G., Bajetta, E., Martinetti, A., Aliberti, G., Pallotti, F., Procopio, G., Torre, S. D., Luksch, R., et al. (2004) · The International Journal of Biological Markers · doi:10.1177/172460080401900407 · Cited by 32
Automated two-site immunofluorescent assay for the measurement of serum chromogranin A
Popovici, T., Moreira, B., Schlageter, M., & Bories, P.-N. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.10.029 · Cited by 25
Belli, S., Oneto, A., Aranda, C., O’Connor, J. M., Domenichini, E., Roca, E. L., Mendez, G. A., Bestani, M. C., Parma, P., Giacomi, N., et al. (2009) · PubMed · Cited by 20
Chromogranin A--serum marker for prostate cancer.
Khan, M. O., & Ather, M. H. (2011) · PubMed · Cited by 18
Nobili, E., Pezzilli, R., Santini, D., Campidelli, C., Calculli, L., Casadei, R., & Biasco, G. (2008) · Case Reports in Gastroenterology · doi:10.1159/000113218 · Cited by 10
Research works printed but not linked: 2
- 10.1210/jcem.82.8.4145 · DOI · Paper page
- 10.1159/000152000 · DOI · Paper page
Cited by
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Neuroendocrine Neoplasms of the Small Bowel and Pancreas
Clift, A. K., Kidd, M. S., Bodei, L., Toumpanakis, C., Baum, R. P., Öberg, K., Modlin, I. M., & Frilling, A. (2019) · Neuroendocrinology · doi:10.1159/000503721 · Cited by 137
Lee, L., Ito, T., & Jensen, R. T. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1693893 · Cited by 81
Chromogranin A: any relevance in neuroendocrine tumors?
Kidd, M. S., Bodei, L., & Modlin, I. M. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000215 · Cited by 70
Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors
Pulvirenti, A., Rao, D. S., McIntyre, C. A., Gönen, M., Tang, L. H., Klimstra, D. S., Fleisher, M., Ramanathan, L. V., Reidy‐Lagunes, D. L., & Allen, P. J. (2018) · HPB · doi:10.1016/j.hpb.2018.09.016 · Cited by 60
Metadata
- Authors
- Jilesen, A. P. J., Busch, O. R. C., van Gulik, T. M., Gouma, D. J., & Nieveen van Dijkum, E. J. M.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Amsterdam Gastroenterology Endocrinology Metabolism (NL)
- Venue
- Digestive Surgery
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 31
- Issue
- 6
- Pages
- 407-414
- ISSN
- 0253-4886 (ISSN-L)
- 1421-9883
- OpenAlex
- W2043740725
- Cited by
- 26
- References
- 44
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 1 · 2016: 2 · 2015: 2
- FWCI
- 0.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Surgery (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- chromogranin A, nonfunctioning pancreatic neuroendocrine tumors, diagnostic accuracy, tumor burden, metastasis detection, false positives, postoperative follow-up
- MeSH terms
- Adult, Aged, False Positive Reactions, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Pancreatic Neoplasms, Postoperative Period, Predictive Value of Tests, Retrospective Studies, Biomarkers, Tumor, Neuroendocrine Tumors, Tumor Burden, Chromogranin A, Preoperative Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.